Trial Profile

A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma - the DUTHY Trial

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 14 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
Indications Carcinoma; Thyroid cancer
Focus Therapeutic Use
Acronyms DUTHY

Most Recent Events

11 Nov 2024 Status changed from active, no longer recruiting to discontinued. ( In compliance with current legislation applicable to Clinical Trials, following the instructions of the Spanish Agency for Medicines and Health Products.)
03 Oct 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
03 Oct 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Jul 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com